DAM
LCTX icon

Deltec Asset Management’s Lineage Cell Therapeutics LCTX Stock Holding History

Deltec Asset Management’s Portfolio LCTX Stock Details LCTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-24,780
Closed -$82K – 159
2015
Q4 		$82K Buy
+24,780
New +$74.1K 0.02% 142

Other funds holding LCTX

BC
Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
MHP
Manatuck Hill Partners Westport, Connecticut $302M AUM 117.41% 1-Year Est. Return
DWM
Destination Wealth Management Walnut Creek, California $4.28B AUM 19.27% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Deltec Asset Management's LCTX Position: Q1 2016 in Review

Deltec Asset Management sold out of Lineage Cell Therapeutics (LCTX) in Q1 2016, closing a stake of 24,780 shares — an estimated $82K sold.

Deltec Asset Management first reported a position in LCTX in Q4 2015 and held it in 1 quarter. The position peaked at $82K in Q4 2015. 66 funds tracked by Wall St. Rank hold LCTX as of Q1 2016.

  • Deltec Asset Management reported no remaining Lineage Cell Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Deltec Asset Management sold 24,780 Lineage Cell Therapeutics shares in Q1 2016, an estimated $82K.
  • Deltec Asset Management first reported a position in Lineage Cell Therapeutics in Q4 2015 and held it in 1 quarter.
  • Deltec Asset Management's Lineage Cell Therapeutics position peaked at $82K in Q4 2015.
  • 66 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q1 2016.

Based on Deltec Asset Management's 13F filing for Q1 2016, filed 27 Apr 2016.